EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies

Pengfei Chen, Xia Li

Frontiers in Pharmacology · 31.07.2024 · 15

DOI: 10.3389/fphar.2024.1430236 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 31.07.2024. Verfasst von Pengfei Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Marine College, Shandong University, Weihai, China. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 173 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atherosclerosis (AS) is the primary pathology behind various cardiovascular diseases and the leading cause of death and disability globally. Recent evidence suggests that AS is a chronic vascular inflammatory disease caused by multiple factors. In this context, the NLRP3 inflammasome, acting as a signal transducer of the immune system, plays a critical role in the onset and progression of AS. The NLRP3 inflammasome is involved in endothelial injury, foam cell formation, and pyroptosis in AS. Therefore, targeting the NLRP3 inflammasome offers a new treatment strategy for AS. This review highlights the latest insights into AS pathogenesis and the pharmacological therapies targeting the NLRP3 inflammasome, focusing on optimal targets for small molecule inhibitors. These insights are valuable for rational drug design and the pharmacological assessment of new targeted NLRP3 inflammasome inhibitors in treating AS.

Schlagwörter

Stichwörter der Autor:innen

NLRP3 inflammasomeatherosclerosismechanismssmall molecule inhibitorstargeted therapies

Autor:innen und Institutionen

  • Marine College, Shandong University, Weihai, China.
  • Shandong Kelun Pharmaceutical Co, Ltd., Binzhou, China.

Zitieren

APA

Chen, P., & Li, X. (2024). NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1430236

Vancouver

Chen P, Li X. NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1430236

BibTeX
@article{Chen2024,
  author = {Chen, Pengfei and Li, Xia},
  title = {NLRP3 inflammasome in atherosclerosis: Mechanisms and targeted therapies},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1430236}
}
Kostenlos starten →